Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-(4-(4-(4-hydroxy-piperidin-1-yl)-phenylamino)-5-oxo-5,6-dihydro-pyrimido(4,5-d)pyridazin-2-yl)-piperidin-4-yl-acetonitrile
2. 4-piperidineacetonitrile, 1-(5,6-dihydro-4-((4-(4-hydroxy-1-piperidinyl)phenyl)amino)-5-oxopyrimido(4,5-d)pyridazin-2-yl)-
3. Asn-002
4. Asn002
1. Asn002
2. Asn-002
3. 1425381-60-7
4. Gusacitinib [inn]
5. Gusacitinib [usan]
6. En3351
7. 4801qyw816
8. En-3351
9. 2-[1-[4-[4-(4-hydroxypiperidin-1-yl)anilino]-5-oxo-6h-pyrimido[4,5-d]pyridazin-2-yl]piperidin-4-yl]acetonitrile
10. 1-(4-(4-(4-hydroxy-piperidin-1-yl)-phenylamino)-5-oxo-5,6-dihydro-pyrimido(4,5-d)pyridazin-2-yl)-piperidin-4-yl-acetonitrile
11. 4-piperidineacetonitrile, 1-(5,6-dihydro-4-((4-(4-hydroxy-1-piperidinyl)phenyl)amino)-5-oxopyrimido(4,5-d)pyridazin-2-yl)-
12. Gusacitinib (usan/inn)
13. Gusacitinib [who-dd]
14. Chembl4594275
15. Schembl14717111
16. Unii-4801qyw816
17. Gtpl10000
18. Asn-002asn-002
19. Bcp31675
20. Ex-a2668
21. Nsc818003
22. Who 10976
23. Nsc-818003
24. Example 189 [wo2013028818a1]
25. Hy-103018
26. Asn-002; Asn 002; Asn002
27. Cs-0023113
28. D11676
29. F78024
30. 2-(1-(4-((4-(4-hydroxypiperidin-1-yl)phenyl)amino)-5-oxo-5,6-dihydropyrimido[4,5-d]pyridazin-2-yl)piperidin-4-yl)acetonitrile
| Molecular Weight | 460.5 g/mol |
|---|---|
| Molecular Formula | C24H28N8O2 |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 5 |
| Exact Mass | 460.23352217 g/mol |
| Monoisotopic Mass | 460.23352217 g/mol |
| Topological Polar Surface Area | 130 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 775 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Gusacitinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Gusacitinib, including repackagers and relabelers. The FDA regulates Gusacitinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Gusacitinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Gusacitinib supplier is an individual or a company that provides Gusacitinib active pharmaceutical ingredient (API) or Gusacitinib finished formulations upon request. The Gusacitinib suppliers may include Gusacitinib API manufacturers, exporters, distributors and traders.
Gusacitinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Gusacitinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Gusacitinib GMP manufacturer or Gusacitinib GMP API supplier for your needs.
A Gusacitinib CoA (Certificate of Analysis) is a formal document that attests to Gusacitinib's compliance with Gusacitinib specifications and serves as a tool for batch-level quality control.
Gusacitinib CoA mostly includes findings from lab analyses of a specific batch. For each Gusacitinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Gusacitinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Gusacitinib EP), Gusacitinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Gusacitinib USP).
LOOKING FOR A SUPPLIER?
